Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2019

01-04-2019 | Myelodysplastic Syndrome | Original Article

Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD)

Authors: Salar Abbas, Sanjay Kumar, Vivi M. Srivastava, Marie Therese M., Sukesh C. Nair, Aby Abraham, Vikram Mathews, Biju George, Alok Srivastava

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2019

Login to get access

Abstract

Bone marrow niche constituents have been implicated in the genesis of clonal hematopoietic dysfunction in myelodysplastic syndromes (MDS), though the exact role of stroma in the pathogenesis of MDS remains to be defined. We have evaluated the characteristics of mesenchymal stromal cells in a cohort of patients with MDS with multilineage dysplasia (MDS-MLD). MSCs were cultured from bone marrow aspirates of MDS-MLD patients and controls with healthy bone marrow. Phenotypic characterization, cell cycle, and apoptosis were analyzed by flow cytometry. Targeted gene expression analysis was done using a reverse-transcription polymerase chain reaction (Q-PCR). MSCs derived from MDS patients (MDS-MSCs) showed normal morphology, phenotype, karyotype and differentiation potential towards adipogenic and osteogenic lineages. However, these MDS-MSCs showed significantly altered cell cycle status and displayed a shift towards increased apoptosis compared to control MSCs (C-MSCs). The gene expression profile of niche responsive/regulatory cytokines showed a trend towards lower expression VEGF, SCF, and ANGPT with no changes in expression of CXCL12A and LIF compared to C-MSCs. The expression levels of Notch signaling components like Notch ligands (JAGGED-1 and DELTA-LIKE-1), receptors (NOTCH1, NOTCH3) and downstream gene (HES1) showed an aberrant expression pattern in MDS-MSCs compared to C-MSCs. Similarly, Q-PCR analysis of Wnt signaling inhibitory ligands (DKK-1 and DKK-2) in MDS-MSCs showed a three-fold increase in mRNA expression of DKK1 and a two-fold increase in DKK2 compared to C-MSCs. These data suggested that MDS-MSCs have an altered proliferation characteristic as well as a dysregulated cytokine secretion and signaling profile. These changes could contribute to the pathogenesis of MDS.
Literature
1.
go back to reference Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317CrossRefPubMed Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317CrossRefPubMed
3.
go back to reference Borovski T, Felipe De Sousa EM, Vermeulen L, Medema JP (2011) Cancer stem cell niche: the place to be. Cancer Res 71:634–639CrossRefPubMed Borovski T, Felipe De Sousa EM, Vermeulen L, Medema JP (2011) Cancer stem cell niche: the place to be. Cancer Res 71:634–639CrossRefPubMed
4.
go back to reference Saki N, Abroun S, Hagh MF, Asgharei F (2011) Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J Yakhteh 13:131 Saki N, Abroun S, Hagh MF, Asgharei F (2011) Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J Yakhteh 13:131
5.
go back to reference Sugiyama T, Kohara H, Noda M, Nagasawa T (2006) Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25:977–988CrossRefPubMed Sugiyama T, Kohara H, Noda M, Nagasawa T (2006) Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25:977–988CrossRefPubMed
6.
7.
go back to reference Zhou BO, Ding L, Morrison SJ (2015) Hematopoietic stem and progenitor cells regulate the regeneration of their niche by secreting Angiopoietin-1. Elife 4:e05521CrossRefPubMedPubMedCentral Zhou BO, Ding L, Morrison SJ (2015) Hematopoietic stem and progenitor cells regulate the regeneration of their niche by secreting Angiopoietin-1. Elife 4:e05521CrossRefPubMedPubMedCentral
8.
go back to reference Flores-Figueroa E, Arana-Trejo RM, Gutiérrez-Espíndola G et al (2005) Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 29:215–224CrossRefPubMed Flores-Figueroa E, Arana-Trejo RM, Gutiérrez-Espíndola G et al (2005) Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 29:215–224CrossRefPubMed
9.
go back to reference Ferrer RA, Wobus M, List C et al (2013) Mesenchymal stromal cells from patients with myelodysplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica 98:1677–1685CrossRefPubMedPubMedCentral Ferrer RA, Wobus M, List C et al (2013) Mesenchymal stromal cells from patients with myelodysplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica 98:1677–1685CrossRefPubMedPubMedCentral
10.
go back to reference Geyh S, Öz S, Cadeddu RP et al (2013) Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 27:1841–1851CrossRefPubMed Geyh S, Öz S, Cadeddu RP et al (2013) Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 27:1841–1851CrossRefPubMed
11.
go back to reference Blau O, Baldus CD, Hofmann W-K et al (2011) Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 118:5583–5592CrossRefPubMedPubMedCentral Blau O, Baldus CD, Hofmann W-K et al (2011) Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 118:5583–5592CrossRefPubMedPubMedCentral
12.
go back to reference Lopez-Villar O, Garcia JL, Sanchez-Guijo FM et al (2009) Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 23:664–672CrossRefPubMed Lopez-Villar O, Garcia JL, Sanchez-Guijo FM et al (2009) Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 23:664–672CrossRefPubMed
13.
go back to reference Flores-Figueroa E, Gutiérrez-Espíndola G, Montesinos JJ et al (2002) In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26:677–686CrossRefPubMed Flores-Figueroa E, Gutiérrez-Espíndola G, Montesinos JJ et al (2002) In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26:677–686CrossRefPubMed
14.
go back to reference Sawanobori M, Yamaguchi S, Hasegawa M et al (2003) Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 27:583–591CrossRefPubMed Sawanobori M, Yamaguchi S, Hasegawa M et al (2003) Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 27:583–591CrossRefPubMed
15.
go back to reference Campioni D, Punturieri M, Bardi A et al (2004) “In vitro” evaluation of bone marrow angiogenesis in myelodysplastic syndromes: a morphological and functional approach. Leuk Res 28:9–17CrossRefPubMed Campioni D, Punturieri M, Bardi A et al (2004) “In vitro” evaluation of bone marrow angiogenesis in myelodysplastic syndromes: a morphological and functional approach. Leuk Res 28:9–17CrossRefPubMed
16.
go back to reference Santamaría C, Muntión S, Rosón B et al (2012) Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 97:1218–1224CrossRefPubMedPubMedCentral Santamaría C, Muntión S, Rosón B et al (2012) Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 97:1218–1224CrossRefPubMedPubMedCentral
17.
go back to reference Pittenger MF, Mackay AM, Beck SC et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147CrossRefPubMed Pittenger MF, Mackay AM, Beck SC et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147CrossRefPubMed
18.
go back to reference Sabapathy V, Ravi S, Srivastava V et al (2012) Long-term cultured human term placenta-derived mesenchymal stem cells of maternal origin display plasticity. Stem Cells Int 2012:174328CrossRefPubMedPubMedCentral Sabapathy V, Ravi S, Srivastava V et al (2012) Long-term cultured human term placenta-derived mesenchymal stem cells of maternal origin display plasticity. Stem Cells Int 2012:174328CrossRefPubMedPubMedCentral
19.
go back to reference Venkatraman A, He XC, Thorvaldsen JL et al (2013) Maternal imprinting at the H19-Igf2 locus maintains adult hematopoietic stem cell quiescence. Nature 500:345–349CrossRefPubMedPubMedCentral Venkatraman A, He XC, Thorvaldsen JL et al (2013) Maternal imprinting at the H19-Igf2 locus maintains adult hematopoietic stem cell quiescence. Nature 500:345–349CrossRefPubMedPubMedCentral
20.
go back to reference Abbas S, Kini A, Srivastava VM et al (2017) Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. Blood Cells Mol Dis 66:37–46CrossRefPubMed Abbas S, Kini A, Srivastava VM et al (2017) Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. Blood Cells Mol Dis 66:37–46CrossRefPubMed
21.
go back to reference Klaus M, Stavroulaki E, Kastrinaki M-C et al (2009) Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev 19:1043–1054CrossRef Klaus M, Stavroulaki E, Kastrinaki M-C et al (2009) Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev 19:1043–1054CrossRef
22.
go back to reference Isern J, Méndez-Ferrer S (2011) Stem cell interactions in a bone marrow niche. Curr Osteoporos Rep 9:210–218CrossRefPubMed Isern J, Méndez-Ferrer S (2011) Stem cell interactions in a bone marrow niche. Curr Osteoporos Rep 9:210–218CrossRefPubMed
23.
go back to reference Shiozawa Y, Havens AM, Pienta KJ, Taichman RS (2008) The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22:941–950CrossRefPubMedPubMedCentral Shiozawa Y, Havens AM, Pienta KJ, Taichman RS (2008) The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22:941–950CrossRefPubMedPubMedCentral
25.
go back to reference Falconi G, Fabiani E, Fianchi L et al (2016) Impairment of PI3 K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. Exp Hematol 44:75–83CrossRefPubMed Falconi G, Fabiani E, Fianchi L et al (2016) Impairment of PI3 K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. Exp Hematol 44:75–83CrossRefPubMed
26.
go back to reference Pavlaki K, Pontikoglou CG, Demetriadou A et al (2014) Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev 23:1568–1581CrossRefPubMed Pavlaki K, Pontikoglou CG, Demetriadou A et al (2014) Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev 23:1568–1581CrossRefPubMed
Metadata
Title
Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD)
Authors
Salar Abbas
Sanjay Kumar
Vivi M. Srivastava
Marie Therese M.
Sukesh C. Nair
Aby Abraham
Vikram Mathews
Biju George
Alok Srivastava
Publication date
01-04-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-1062-6

Other articles of this Issue 2/2019

Indian Journal of Hematology and Blood Transfusion 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine